araag2/HINT huggingface dataset:
Clinical trial NCT00057954 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pentostatin, cyclosporin (csa), mycophenolate mofetil (mmf), methotrexate (mtx)
SMILES: OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, COC(=O)\C=C\C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Non-Hodgkin's or Hodgkin's lymphoma that has relapsed following either a course of
             high dose chemotherapy or autologous stem cell transplantation.

          -  >= 90 days from prior transplant.

          -  Have a suitable human leukocyte antigen (HLA)-matched related bone marrow donor or a
             compatible matched unrelated bone marrow donor by molecular typing at HLA A, B, C, D,
             DR.

          -  Physically and psychologically capable of undergoing bone marrow transplantation and
             its attendant period of strict isolation.

          -  Age >= 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Be able to receive 400 cGy Total Body Irradiation (TBI).

          -  Pulmonary function tests: Diffusing capacity or Transfer factor of the lung for carbon
             monoxide (DLCO) >= 50% predicted, the forced expiratory volume in 1 second (FEV1) >=
             50% predicted.

          -  Left ventricular ejection fraction (LVEF) at least 45% by Multi Gated Acquisition Scan
             (MUGA) or echocardiogram.

          -  Renal function: creatinine clearance > 50 ml/min.

          -  Liver function tests: < 3 x Upper Limit of Normal (ULN). Liver function test include
             serum glutamic oxaloacetic transaminase (SGOT) (Aspartate transaminase (AST)), Serum
             Glutamic Pyruvate Transaminase (SGPT) (Alanine transaminase (ALT)), and bilirubin.

        Exclusion Criteria:

          -  Human immunodeficiency virus positive (HIV+) patients (test positive for P21
             antibodies to HIV).

          -  Evidence of active infection (have received parenteral antibiotics <= 2 weeks prior to
             registration).

          -  Pregnant or breast-feeding women.

          -  Curable with any other therapeutic interventions.
Clinical trial NCT00538291 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    study was terminated early due to lack of efficacy.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of metastatic colorectal cancer

          -  Measurable disease

          -  Disease progression during prior fluoropyrimidine-containing therapy comprising
             irinotecan with or without oxaliplatin

               -  Received standard first- and second-line irinotecan and oxaliplatin-based therapy

                    -  Patients who completed 1 prior treatment for metastatic disease but refused
                       standard second-line therapy are eligible

               -  Patients who's disease progressed within 6 months of previous therapy are
                  eligible

          -  EGFR negative patients allowed

          -  No untreated or uncontrolled brain metastasis

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Absolute neutrophil count ≥ 1,500/μL

          -  Platelet count ≥ 100,000/μL

          -  ALT ≤ 5 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 5 times ULN

          -  Serum creatinine ≤ 1.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other prior malignancy within the past 5 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  No serious intercurrent infections or medical problems

          -  No active or uncontrolled infections

          -  No significant history of uncontrolled cardiac disease, including any of the
             following:

               -  Uncontrolled hypertension

               -  Unstable angina

               -  Myocardial infarction within the past 6 months

               -  Uncontrolled congestive heart failure

               -  Cardiomyopathy with decreased ejection fraction

          -  No prior severe infusion reaction to a monoclonal antibody

          -  No known dihydropyrimidine dehydrogenase deficiency or evidence of past
             hypersensitivity to fluoropyrimidine

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No more than 2 prior treatments for metastatic colorectal cancer

          -  More than 2 weeks since prior therapy

          -  Prior radiotherapy allowed if < 30% of bone marrow involvement

          -  No other concurrent investigational agents

          -  No concurrent highly active antiretroviral therapy for HIV-positive patients

          -  No prior therapy that specifically and directly targets the EGFR pathway
Clinical trial NCT00524589 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    closed due to futility
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  History of androgen-independent prostate cancer

               -  Evidence of rising PSA level (with or without new lesion by radiograph or
                  physical examination), defined as follows:

                    -  PSA level > 5 ng/mL and clearly rising on 2 measurements taken ≥ 2 weeks
                       apart after androgen deprivation therapy (i.e., orchiectomy or luteinizing
                       hormone-releasing hormone [LHRH] analogue) and antiandrogen withdrawal, if
                       appropriate

               -  PSA rising before and on the first value taken at 4 or 6 weeks after antiandrogen
                  cessation is considered disease progression

          -  Measurable or evaluable disease as defined by any of the following:

               -  Measurable or evaluable tumor masses by radiograph or physical examination

               -  Evaluable PSA

          -  Concurrent LHRH analogue or diethylstilbestrol (DES) for testicular androgen
             suppression required if no prior bilateral orchiectomy

               -  Patients receiving other monotherapy for testicular androgen suppression must
                  switch to a LHRH analogue or DES ≥ 14 days prior to study entry

        PATIENT CHARACTERISTICS:

          -  ECOG 0-2

          -  Life expectancy ≥ 12 weeks

          -  ANC ≥ 1,000/mm³

          -  Platelet count ≥ 75,000/mm³

          -  Hemoglobin > 8.9 g/dL (transfusion or erythropoietin support allowed)

          -  Serum creatinine ≤ 1.8 mg/dL

          -  AST ≤ 4 times upper limit of normal (ULN)

          -  Total bilirubin ≤ 2.0 mg/dL

          -  Serum corrected calcium < ULN

          -  No history of nephrolithiasis within the past 5 years

          -  No unstable, uncontrolled peptic ulcer disease, congestive heart failure, glaucoma,
             HIV, or diabetes

        PRIOR CONCURRENT THERAPY:

          -  At least 28 days since prior androgen deprivation therapy (≥ 42 days for bicalutamide)

               -  A 28-day washout period is not required for patients who have previously
                  progressed despite antiandrogen withdrawal and who have resumed antiandrogens
                  without reduction of PSA

          -  At least 14 days since prior radiotherapy

          -  At least 28 days since prior strontium 89

          -  At least 28 days since prior chemotherapy and/or investigational agents

          -  No concurrent medications or supplements that contain additional calcium (e.g., Tums)

          -  No concurrent radiotherapy for pain control or any other indication

          -  Concurrent bisphosphonates allowed provided dose/regimen is stable
Clinical trial NCT01338883 (phase 2, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: cenicriviroc 100 mg, cenicriviroc 200 mg + truvada, sustiva + truvada
SMILES: CCCCOCCOC1=CC=C(C=C1)C1=CC=C2N(CC(C)C)CCC\C(=C/C2=C1)C(=O)NC1=CC=C(C=C1)[S@@+]([O-])CC1=CN=CN1CCC, CCCCOCCOC1=CC=C(C=C1)C1=CC=C2N(CC(C)C)CCC\C(=C/C2=C1)C(=O)NC1=CC=C(C=C1)[S@@+]([O-])CC1=CN=CN1CCC, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Selected Inclusion Criteria:

          1. Adult male and female, HIV-1-infected patients 18 years old and older.

          2. Body mass index (BMI) 18 to < 35 kg/m2.

          3. Antiretroviral treatment-naïve. Treatment-naïve is defined as:

               -  No prior nonnucleoside reverse transcriptase inhibitor, other than in women who
                  received a single dose of perinatal nevirapine who have no K103 viral mutation.

               -  No prior CCR5 antagonist therapy.

               -  No more than 10 days of any other prior antiretroviral therapy.

          4. HIV-1 CCR5-tropic-only virus.

          5. Plasma HIV-1 RNA level >/=1,000 copies/mL at first Screening.

          6. CD4 cell count >/=250 cells/mm3 at first Screening.

        Selected Exclusion Criteria:

          1. Presence of CXCR4- or dual/mixed-tropic HIV-1 virus.

          2. Presence of primary resistance mutations or phenotypic resistance to TDF, FTC, or EFV
             and/or mutations associated with multidrug nucleoside/nucleotide resistance.

          3. An active CDC category C disease (except cutaneous Kaposi's sarcoma not requiring
             systemic therapy during the trial).

          4. Any historical CD4 count < 200 cells/mm3.

          5. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value Grade >
             2 or total bilirubin greater than the upper limit of normal (ULN).

          6. History of HIV-2, hepatitis B and/or C, cirrhosis of the liver, or any known active or
             chronic liver disease. Hepatitis B vaccinated patients are eligible.
Clinical trial NCT01095757 (phase 2, status: completed)
Conditions: myeloma, lymphoma
ICD codes: C90.01, C90.02, C90.00, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: plerixafor
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18-70 years

          2. Multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) patients in first or second
             complete or partial remission

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          4. Up to 3 prior treatment regimens

          5. Meet all eligibility requirements for autologous transplant

          6. Adequate marrow function defined as white blood cells (WBC) >3,000; ANC >1,500/mm3;
             platelets >75,000/mm3

          7. Adequate renal function defined as creatinine clearance > 30 mL/min by Cockcroft-Gault

          8. Adequate liver function defined as aspartate aminotransferase (AST)/alanine
             aminotransferase (ALT)/bilirubin < 2 times upper limit of normal

          9. Able to provide informed consent

         10. Women not pregnant and agree to use contraception

        Exclusion Criteria:

          1. High risk co-morbidities for acute treatment complications (e.g., symptomatic coronary
             artery disease)

          2. Brain metastases or carcinomatous meningitis

          3. Previous treatment with high dose chemotherapy and autologous transplant

          4. Previous attempt to collect B-hematopoietic progenitor cells (HPCs) following
             mobilization with growth factors alone, growth factors and chemotherapy, or plerixafor
             and growth factors

          5. Acute infection or unexplained fever >38°C

          6. Weight > 175% of ideal body weight as defined by the Devine equation

          7. Experimental therapy within 4 weeks

          8. Cytokine administration in the previous 14 days
Clinical trial NCT01753752 (phase 2, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: chitosan- n- acetylcysteine eye drops, placebo
SMILES: CC(=O)N[C@@H](CS)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women aged over 18 years

          -  History of dry eye syndrome for at least 3 months

          -  At least two of the following three criteria must apply: - Tear Break Up Time (BUT) <
             10 seconds and/or - Schirmer I test < 7 mm and/or - at least 2 symptoms of dry eye
             syndrome (foreign body sensation, burning, photophobia, blurred vision, pain, itching)

          -  Normal ophthalmic findings except dry eye syndrome, ametropia < 6 Dpt.

          -  No administration of topical lubricants 24 hours before the screening examination

        Exclusion Criteria:

          -  Participation in a clinical trial in the 3 weeks preceding the screening visit

          -  Symptoms of a clinically relevant illness other than dry eye in the 3 weeks before the
             first study day

          -  Presence or history of a severe medical condition as judged by the clinical
             investigator

          -  Intake of parasympathomimetic or anti-psychotic drugs

          -  Diagnosis of severe dry eye by Schirmer I test < 2mm

          -  Difference in BUT between the two eyes of more than 4 seconds

          -  Wearing of contact lenses

          -  Glaucoma

          -  Treatment with corticosteroids in the 4 weeks preceding the study

          -  Topical treatment with any ophthalmic drug except topical lubricants in the 4 weeks
             preceding the study

          -  Ocular infection or clinically significant inflammation

          -  Ocular surgery in the 3 months preceding the study

          -  Sjögren's syndrome

          -  Stevens-Johnson syndrome

          -  History of allergic conjunctivitis

          -  Ametropia ≥ 6 Dpt

          -  Pregnancy, planned pregnancy or lactating
Clinical trial NCT00334802 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically and/or cytologically confirmed breast cancer

          -  Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline
             regimen

          -  To have at least one measurable region

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1

          -  To have adequate organ function (bone marrow, liver and renal function)

        Exclusion Criteria:

          -  To have interstitial pneumonia or pulmonary fibrosis

          -  To have inflammatory breast cancer

          -  Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest
             hormonal/immunotherapy or 7 days after surgery

          -  To have brain metastases with symptoms

          -  To have severe complication (cardiac infarction, infection, drug hypersensitivity or
             diabetes)
Clinical trial NCT00381693 (phase 2, status: terminated)
Conditions: chronic myeloproliferative disorders, secondary myelofibrosis
ICD codes: D47.1, D75.81, C94.41, C94.42, C94.40
Drugs: azacitidine
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Reason stopped: 
    due to lack of accrual and trial has demonstrated too little clinical benefit
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed myelofibrosis with myeloid metaplasia (MMM), including any of
             the following subtypes:

               -  Agnogenic myeloid metaplasia

               -  Post-polycythemic myeloid metaplasia

               -  Post-thrombocythemic myeloid metaplasia

          -  Evaluable and symptomatic disease, defined as 1 of the following:

               -  Anemia (hemoglobin < 10 g/dL or erythrocyte transfusion-dependent, requiring 1
                  transfusion ≤ 8 weeks)

               -  Treatment required* for symptomatic palpable splenomegaly (palpable hepatomegaly
                  is acceptable if previously splenectomized) NOTE: *Subjective but painful enough
                  to mandate intervention

          -  Absence of t(9;22) by fluorescent in situ hybridization (FISH) or standard
             cytogenetics (by peripheral blood or marrow)

             - Previous demonstration of a lack of this translocation (at any point) is sufficient

          -  No advanced malignant hepatic tumors

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Absolute neutrophil count ≥ 1,000/mm³

          -  Platelet count ≥ 50,000/mm³

          -  Creatinine ≤ 2.0 mg/dL

          -  Total bilirubin ≤ 2.0 mg/dL OR direct bilirubin ≤ 2.0 mg/dL if total bilirubin
             elevated (unless attributed to underlying disease)

          -  AST and ALT ≤ 2 times upper limit of normal (unless clinically attributed to hepatic
             extramedullary hematopoiesis)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No baseline peripheral or autonomic neuropathy ≥ grade 2

          -  No condition, including the presence of laboratory abnormalities, that would preclude
             study compliance

          -  No hypersensitivity to mannitol or azacitidine

          -  Not incarcerated in a municipality (i.e., county, state, or federal prison)

        PRIOR CONCURRENT THERAPY:

          -  At least 14 days since prior chemotherapy, including interferon alfa, anagrelide, or
             other myelosuppressive agents

          -  At least 14 days since prior systemic corticosteroids

          -  At least 14 days since prior investigational agents
Clinical trial NCT01424319 (phase 2, status: completed)
Conditions: chronic kidney disease, diabetic nephropathy
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, E10.21, E11.21, E13.21, E08.21, E09.21
Drugs: atrasentan low dose group, atrasentan high dose group, atrasentan placebo group
SMILES: CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C1=CC=C(OC)C=C1)C(O)=O)C1=CC2=C(OCO2)C=C1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C1=CC=C(OC)C=C1)C(O)=O)C1=CC2=C(OCO2)C=C1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C1=CC=C(OC)C=C1)C(O)=O)C1=CC2=C(OCO2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has Type 2 diabetes and has been treated with at least one anti-hyperglycemic
             medication within the 12 months prior to the screening period.

          -  Patient is receiving a maximum tolerated labeled dose of an ACEi (Angiotensin
             Converting Enzyme inhibitor) or ARB (Angiotensin II Receptor Blocker)(Renin
             Angiotensin System (RAS) inhibitor). Estimated GFR (Glomerular Filtration Rate) is
             greater than or equal to 30 and less than or equal to 75 mL/min/1.73m2 by the CKD
             (chronic kidney disease)

          -  Epidemiology Collaboration (EPI) formula.

          -  UACR (Urinary Albumin to Creatinine Ratio) is greater than or equal to 200 mg/g as
             determined by the geometric mean of the three morning void urine specimens obtained at
             Run-in period.

          -  Serum albumin is greater than or equal to 3.0 g/dL. BNP (B-type Natriuretic Peptide)
             is less than or equal to 200 pg/mL.

          -  SBP (Systolic Blood Pressure) is greater than or equal to 110 mmHg and less than or
             equal to 160 mmHg. HbA1c (Glucosylated Hemoglobin A1c) is less than or equal to 12%
             and serum potassium is less than or equal to 5.5 mEq/L.

        Exclusion Criteria:

          -  Patient has a history of moderate or severe edema, facial edema unrelated to trauma,
             or a history of myxedema in the prior 6 months to screening.

          -  Patient is receiving loop diuretics greater than or equal to 120 mg QD (Once Daily) of
             furosemide or greater than or equal to 3.0 mg QD (Once Daily) of bumetanide or greater
             than or equal to 150 mg QD (Once Daily) of ethacrynic acid or greater than or equal to
             60 mg QD (Once Daily) of torasemide.

          -  Patient has a documented history of Stage C or Stage D heart failure, defined ACC/AHA
             (American College of Cardiology/ American Heart Association Practice Guidelines).

          -  Patient is receiving any of a combination of an ACEi (Angiotensin Converting Enzyme
             inhibitor) and ARB (Angiotensin II Receptor Blocker) or rosiglitazone or aliskiren or
             an aldosterone antagonist and patient is receiving pioglitazone and edema is present.
Clinical trial NCT01230476 (phase 2, status: terminated)
Conditions: nasopharyngeal carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  Inpatients or outpatients, 18-65 years of age

          -  Histologically confirmed, newly diagnosed locally advanced (UICC/AJCC stage III to
             IVB) nasopharyngeal carcinoma requiring radiotherapy

          -  Evidence of unidimensional measurable disease as per RECIST criteria

          -  No systemic metastatic disease (M0)

          -  ECOG performance status of 0 or 1 at study entry

          -  Effective contraception

          -  White blood cell count ≥ 3,000/mm3 with neutrophils ≥1,500/mm3, platelet count
             ≥100,000/mm3, hemoglobin ≥ 5.6 mmol/L (9 g/dL)

          -  Total bilirubin ≤ 1.5x upper reference range

          -  AST & ALT ≤ 1.5x upper reference range

          -  Glomerular filtration rate > 60 ml/min

          -  Serum creatinine ≤ 1.25x upper reference range

        Exclusion Criteria:

          -  Previous radiotherapy, chemotherapy, surgery (excluding diagnostic biopsy) or any
             investigational drug for the NPC

          -  Concurrent chronic systemic immune therapy, targeted therapy, anti-VEGF therapy or
             EGFR-pathway targeting therapy not indicated in this study protocol

          -  Known hypersensitivity reaction to any of the components of study treatments

          -  Pregnancy or lactation period

          -  Systemic metastatic disease

          -  Clinically relevant coronary artery disease, history of myocardial infarction in the
             last 12 months, or high risk of uncontrolled arrhythmia

          -  Peripheral neuropathy > grade 1

          -  Previous malignancy except basal cell cancer of the skin or preinvasive cancer of the
             cervix

          -  Known alcohol or drug abuse

          -  Medical or psychological conditions that would not permit the patient to complete the
             study or sign informed consent

          -  Legal incapacity or limited legal capacity